Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Pharma Leaders Air Grievances on Pricing Reform Package at New MHLW Confab
Chieftains of major drug makers and industry associations fired off a barrage of complaints against the 2018 drug pricing reform package at their new policy dialogue forum with senior health ministry officials on April 16, with Eisai CEO Hauro Naito…
To read the full story
Related Article
- No Dialogue at New “Public-Private Dialogue” Confab with Limited Time, JPMA Says
April 20, 2018
- Generic Industry Asks for Govt Support for Continuous Manufacturing to Boost Int’l Competitiveness: Public-Private Confab
April 17, 2018
- No Company Supports New Price Maintenance Premium Scheme: FPMAJ Survey
April 17, 2018
- MHLW to Launch New Public-Private Confab Focusing on Drug Pricing
April 10, 2018
REGULATORY
- Officer Replacement Orders a “Last Resort” under PMD Act: MHLW Official
September 18, 2026
- Japan Panel Sees No Scientific Objection to Capvaxive NIP Addition
September 18, 2026
- Tavneos Blue Letter Action “Too Slow,” MHLW Panel Member Says
September 18, 2026
- Takaichi Tasks Ueno with Charting Growth Strategy for Drug Innovation
September 18, 2026
- Japan HIV, AIDS Cases Rise in H1 after 2025 Lows
September 18, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…